A Double-Blind Comparison of Olanzapine Versus Risperidone in the Acute Treatment of Dementia- Related Behavioral Disturbances in Extended Care Facilities
J Clin Psychiatry 2003;64:726-730
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: In addition to demonstrating their
superiority to placebo, there is a need to compare the relative
efficacy and side effects of atypical neuroleptics for the acute
treatment of dementia-related behavioral disturbances in
residents of long-term care facilities.
Method: In a double-blind parallel study
allowing dose titration over 14 days, 39 agitated persons with
DSM-IV dementia who were residing in long-term care facilities
were administered olanzapine (N = 20) or risperidone (N = 19) as
acute treatment. Drug was administered once a day at bedtime. The
initial dosages were olanzapine, 2.5 mg/day, and risperidone, 0.5
mg/day. Titration was allowed to maximum doses of olanzapine, 10
mg/day, and risperidone, 2.0 mg/day. The primary outcome measures
were the Clinical Global Impressions scale (CGI) and the
Neuropsychiatric Inventory (NPI). Data were gathered from 2000 to
Results: Both drugs produced significant
reductions in CGI and NPI scores (p < .0001), but there was no
significant difference between drugs. The mean olanzapine dose
was 6.65 mg/day; for risperidone, the dose was 1.47 mg/day. The
positive drug effect was not accompanied by decreased mobility,
and there was improvement on a quality-of-life measure. The chief
adverse events were drowsiness and falls. At baseline, 42%
(16/38) of subjects in both groups had extrapyramidal symptoms
that increased slightly, but not significantly, by the end of the
Conclusion: Low-dose, once-a-day olanzapine and
risperidone appear to be equally safe and equally effective in
the treatment of dementia-related behavioral disturbances in
residents of extended care facilities.